Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11890325 Therapeutic uses of dulaglutide

Patent 11890325 was granted and assigned to Eli Lilly and Company on February, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Jeffrey S. Riesmeyer0

David Bradley Woodward0

Date of Patent

February 6, 2024

0

Patent Application Number

175996210

Date Filed

November 4, 2019

0

Patent Citations

US Patent 9949997 Pharmaceutical composition, methods for treating and uses thereof

0

US Patent 7084243 Glucagon-like peptide-1 analogs

0

US Patent 7271149 GLP-1 fusion proteins

0

US Patent 7452966 GLP-1 analog fusion proteins

0

US Patent 9968659 Liraglutide in cardiovascular conditions

0

Patent Primary Examiner

0

CPC Code

0

0

0

Patent abstract

The present invention relates to methods for reducing the risk of major adverse cardiovascular events in type 2 diabetes mellitus (T2DM) patients with multiple cardiovascular risk factors without established cardiovascular disease or with established cardiovascular disease comprising administering the glucagon like peptide-1 (GLP-1) receptor agonist dulaglutide.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11890325 Therapeutic uses of dulaglutide

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool